IRIS
MONTI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 931
EU - Europa 541
AS - Asia 235
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.711
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 923
IE - Irlanda 315
CN - Cina 209
FI - Finlandia 58
DE - Germania 53
IT - Italia 53
SE - Svezia 21
AT - Austria 18
SG - Singapore 15
CA - Canada 8
CZ - Repubblica Ceca 5
IN - India 5
BE - Belgio 4
GB - Regno Unito 4
RU - Federazione Russa 3
UA - Ucraina 3
DZ - Algeria 2
ES - Italia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
DK - Danimarca 1
IR - Iran 1
JP - Giappone 1
KR - Corea 1
SA - Arabia Saudita 1
VN - Vietnam 1
Totale 1.711
Salva come PNG Salva come JPEG
Città #
Dublin 312
Chandler 309
Ashburn 78
Princeton 51
Helsinki 49
Lawrence 46
Beijing 45
Shanghai 40
New York 39
Nanjing 34
Jacksonville 28
Wilmington 28
Medford 27
Nanchang 18
Vienna 16
Changsha 15
Pavia 13
Seattle 13
Chicago 11
Fairfield 11
Hebei 11
Singapore 10
Jiaxing 9
Washington 9
Hangzhou 8
Shenyang 8
Los Angeles 7
Milan 6
Toronto 6
Brno 5
Norwalk 5
Tianjin 5
Berlin 4
Brussels 4
Cagliari 4
Redwood City 4
San Francisco 4
Ann Arbor 3
Genoa 3
Turin 3
Woodbridge 3
Borås 2
Esslingen am Neckar 2
Philadelphia 2
Porcia 2
Pune 2
Tizi Ouzou 2
Valencia 2
Venice 2
Bangalore 1
Bovisio Masciago 1
Brierley Hill 1
Buffalo 1
Busto Arsizio 1
Cedar Knolls 1
Charleston 1
Chengdu 1
Clifton 1
Des Moines 1
Dong Ket 1
Guangzhou 1
Haikou 1
Houston 1
Jinan 1
London 1
Mcallen 1
Melbourne 1
Munich 1
Nanning 1
Ningbo 1
Orange 1
Piscataway 1
Redmond 1
Riyadh 1
Saint Petersburg 1
Sarajevo 1
Tokyo 1
Veruno 1
Victoria 1
Wuhan 1
Yerevan 1
Zelo Buon Persico 1
Zibo 1
Totale 1.354
Salva come PNG Salva come JPEG
Nome #
Is it really infective endocarditis? Distinguishing systemic vasculitis from its mimics 55
20 years of experience with tumour necrosis factor inhibitors: what have we learned? 54
Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs 49
Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse 47
Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis 47
Clinical spectrum of anti-Jo-1-associated disease 46
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors 45
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 45
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 45
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 44
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 43
Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis 42
Chronic pain: The burden of disease and treatment innovations 41
Switching from intravenous to subcutaneous formulation of abatacept: Different results in a series of 21 patients 40
Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management 39
Early development of new cardiovascular risk factors in the systemic vasculitides 39
The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature 39
Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis 38
Remission and Low-Disease Activity in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual 37
Clinical course and outcome of COVID-19 in patients with rheumatic diseases: Are all biological disease-modifying antirheumatic drugs alike? Response to: Â € Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al 37
Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak 37
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 37
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 37
Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners 37
Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature 36
Novel Therapies for ANCA-associated Vasculitis 36
Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis 35
Pneumocephalus due to granulomatosis with polyangiitis 33
Lumbar spondylolisthesis associated with systemic sclerosis-related spinal calcinosis: an unusual clinical case 33
The role of Trimethoprim/sulfametoxazole in reducing relapses and risk of infec-tions in ANCA-associated vasculitis: a meta-analysis 33
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 33
Retention rate of IL-1 inhibitors in Schnitzler's syndrome 33
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: Ͽ Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and SLE, hydroxychloroquine and no SLE patients with COVID-19: A comment' by Joob and Wiwanitkit 32
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: Lessons from a case with severe pneumonia' by Guilpain et al 31
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies 30
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al 30
Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment 29
Cytomegalovirus colitis unmasking human immunodeficiency virus infection as a cause of IgA vasculitis 28
Pneumocephalus due to granulomatosis with polyangiitis 28
How I treat idiopathic patients with inflammatory myopathies in the clinical practice 27
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al 27
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis 27
Striking abdominal aortic stenosis revealing Takayasu's arteritis 26
Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? 25
Response to: 'Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler et al 23
Novel Diagnostic and Prognostic Approaches to Systemic Vasculitides 23
Development and implementation of the AIDA International Registry for patients with Behçet’s disease 20
Prevalence of COVID-19 among patients with rheumatic diseases: The need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al 19
Non-steroidal anti-inflammatory treatment during covid-19: Friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al 16
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 15
Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study 14
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 12
Updates on the diagnosis and monitoring of giant cell arteritis 5
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients 3
Humoral and T-cell immune response following three doses of SARS-CoV-2 mRNA vaccine in giant cell arteritis: analysis of a prospective cohort 2
Totale 1.784
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.113
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.113
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020170 48 63 0 0 0 0 2 0 1 28 28 0
2020/202180 0 0 12 3 2 10 1 19 0 13 13 7
2021/2022203 4 1 13 2 4 14 1 11 9 6 27 111
2022/2023859 87 82 6 68 73 80 3 42 375 9 18 16
2023/2024396 63 75 18 16 30 83 25 32 3 20 15 16
2024/202528 28 0 0 0 0 0 0 0 0 0 0 0
Totale 1.784